No material company-specific news briefings were available for Amgen Inc. in the period leading to this report's generation date of 11 September 2026. The report was triggered primarily by material institutional position changes identified in recent 13F filings.
Amgen's trailing twelve-month revenue stood at $38.10 billion as of 30 June 2026, representing year-over-year growth of 9.53% [SEC 10-Q - AMGN - 2026-06-30]. Net income over the same period reached $8.74 billion, translating to a net margin of 22.95% and an operating margin of 29.99%. Gross margin was recorded at 47.46%. Earnings per share grew 64.91% year-over-year. The company held $13.99 billion in cash against total debt of $59.30 billion. Market capitalisation was approximately $206.76 billion, with a price-to-earnings ratio of 23.77 [SEC 10-Q - AMGN - 2026-06-30].
Insider activity over the past 30 days consisted of two transactions, both in the selling direction, with a combined net value of approximately -$521,365 [SEC Form 4 - AMGN - 2026-09]. On the institutional side, several notable 13F position changes were recorded. Citadel added approximately 60% to its existing position, and AQR Capital nearly doubled its holding with a 97% addition. Bridgewater increased its position by 48%. Conversely, Millennium reduced its position by 36% [SEC 13F - Citadel - Q2 2026; SEC 13F - AQR Capital - Q2 2026; SEC 13F - Bridgewater - Q2 2026; SEC 13F - Millennium - Q2 2026].
The prevailing macro environment as of the report date shows the 10-year US Treasury yield (DGS10) at 4.83% and the 2-year yield (DGS2) at 4.39%, producing a normal yield curve with a spread of 44 basis points [FRED DGS10; FRED DGS2]. Amgen carries a substantial long-term debt load of $59.30 billion, making the prevailing interest rate environment a relevant backdrop for assessing its financing costs [SEC 10-Q - AMGN - 2026-06-30].